The DOI matches its Crossref record.
Ototoxicity From Cisplatin Therapy in Childhood Cancer
Abstract
Cisplatin has been associated with hearing damage. It is usually irreversible, bilateral, and characterized by high-frequency sensorineural hearing loss. This study was carried out to identify impairment of hearing function in children and adolescents with cancer after cisplatin therapy. Twenty-three survivors of childhood cancer treated with cisplatin at our Unit from 1991 to 2004 performed tympanometry, pure tone audiometry, transient otoacoustic emissions, and distortion product otoacoustic emissions (DPOAE). The median age at diagnosis was 12.3 years and the median total dose of cisplatin received was 406 mg/m2. Fifty-two percent of patients had bilateral and in the high frequencies range hearing loss on audiometry. Transient otoacoustic emission and DPOAE abnormalities were detected in 22% and in 71% of the patients, respectively. We found a high concordance between the findings of audiometry and DPOAE (P=0.01). There was no influence of sex and number of ototoxic drugs other than cisplatin on hearing loss. There was a trend for younger age and higher cumulative dose of cisplatin to be associated with greater severity of hearing damage. Our data provide further evidence on hearing damage due to cisplatin therapy in children. The high incidence of patients with hearing function abnormalities found in this study and in previous reports highlights the importance of monitoring hearing function in children and adolescents undergoing cisplatin therapy, or as early as possible at follow-up. This study also demonstrates that DPOAE should be used for screening of hearing abnormalities and, once hearing damage is identified, patients require expert audiologic pediatric evaluation and (where indicated) use of hearing aids and/or speech therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Chemotherapy Side-Effects: Not All DNA Damage Is Equal
van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P. (2022) · Cancers · doi:10.3390/cancers14030627 · Cited by 458
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417
Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection
Sheth, S., Mukherjea, D., Rybak, L. P., & Ramkumar, V. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00338 · Cited by 361
the CPNDS Consortium, Ross, C. J. D., Katzov-Eckert, H., Dubé, M.-P., Brooks, B., Rassekh, S. R., Barhdadi, A., Feroz-Zada, Y., Visscher, H., Brown, A. M. K., et al. (2009) · Nature Genetics · doi:10.1038/ng.478 · Cited by 327
Lustberg, M. B., Kuderer, N. M., Desai, A., Bergerot, C., & Lyman, G. H. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00776-9 · Cited by 306
Metadata
- Authors
- Coradini, P. P., Cigana, L., Selistre, S. G. A., Rosito, L. S., & Brunetto, A. L.
- Venue
- Journal of Pediatric Hematology/Oncology
- Published
- 2007-06
- Volume
- 29
- Issue
- 6
- Pages
- 355-360
- ISSN
- 1077-4114 (ISSN-L)
- OpenAlex
- W1990815686
- Cited by
- 175
- References
- 0
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ototoxicity From Cisplatin Therapy in Childhood Cancer. https://app.cochat.ai/papers/10.1097/mph.0b013e318059c220
- The paper
- Coradini, P. P., Cigana, L., Selistre, S. G. A., Rosito, L. S., & Brunetto, A. L. (2007). Ototoxicity From Cisplatin Therapy in Childhood Cancer. Journal of Pediatric Hematology/Oncology. https://doi.org/10.1097/mph.0b013e318059c220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.